We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Study data published in the NEJM reveal that Bayer and Johnson & Johnson's cardiovascular drug Xarelto did not reduce the rate of blood clots in certain high-risk patients, as reported Channel News Asia Sunday.